Global Allergy Diagnostics Markets, 2022-2026 & 2031 with BioMerieux, Danaher, HOB Biotech Group, HYCOR Biomedical, & Lincoln Diagnostics Dominating
23 juin 2022 04h18 HE | Research and Markets
Dublin, June 23, 2022 (GLOBE NEWSWIRE) -- The "Allergy Diagnostics Global Market Report 2022, By Allergen, By Products, By End User" report has been added to ResearchAndMarkets.com's offering.The...
intrommune_icon_500x500.png
Intrommune Announces Expanded Scope of Phase 1 OMEGA Study in Adults with Peanut Allergy
22 juin 2022 09h31 HE | Intrommune Therapeutics
Amendment to Extend Study Duration to 48 weeks New Maintenance Period Is Designed to Evaluate Safety of INT301 After Long-term Exposure NEW YORK, June 22, 2022 (GLOBE NEWSWIRE) -- Intrommune...
AB Science today announced publication of results from its positive study of masitinib in severe asthma uncontrolled by oral corticosteroids in the peer-reviewed Journal of Asthma and Allergy
07 juin 2022 11h45 HE | AB Science
PRESS RELEASE AB SCIENCE ANNOUNCES PUBLICATION IN THE JOURNAL OF ASTHMA AND ALLERGY OF POSITIVE MASITINIB PHASE 3 CLINICAL TRIAL RESULTS IN PATIENTS WITH ORAL CORTICOSTEROID-DEPENDENT SEVERE ASTHMA ...
AB Science annonce aujourd'hui la publication des résultats de son étude positive du masitinib dans l'asthme sévère non contrôlé par les corticostéroïdes oraux dans la revue évaluée par des pairs Journal of Asthma and Allergy
07 juin 2022 11h45 HE | AB Science
COMMUNIQUE DE PRESSE AB SCIENCE ANNONCE LA PUBLICATION DANS LA REVUE JOURNAL OF ASTHMA AND ALLERGY DES RÉSULTATS POSITIFS DE L'ETUDE DE PHASE 3 DU MASITINIB CHEZ LES PATIENTS SOUFFRANT D'ASTHME...
22157.jpg
Global Allergy Diagnostics Market Report 2022: Market to Reach US$5.7 Billion by 2026 - Increasing Prevalence and Incidence of Allergic Disorders to Drive the Demand
07 juin 2022 05h48 HE | Research and Markets
Dublin, June 07, 2022 (GLOBE NEWSWIRE) -- The "Allergy Diagnostics - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. Global Allergy Diagnostics...
22157.jpg
Global Allergen Blocker Market Report to 2027 - Featuring Trutek, Prestige Brands and Ecology Works Among Others
07 juin 2022 04h53 HE | Research and Markets
Dublin, June 07, 2022 (GLOBE NEWSWIRE) -- The "Allergen Blocker Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2027" report has been added to ResearchAndMarkets.com's...
Axim-Sapphire_Logo_-04 (1).png
AXIM Biotechnologies Completes Optimization of Only FDA-Cleared IgE Rapid Diagnostics Test – In-House Manufacturing Lowers Cost and Eliminates Supply Chain Expenditures
24 mai 2022 09h00 HE | AXIM BIOTECHNOLOGIES, INC
SAN DIEGO, May 24, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting ocular surface...
Worldwide Allergy Immunotherapy Industry to 2028 - Increasing Approval of Allergy Immunotherapy by Regulatory Authorities are Driving Growth
28 avr. 2022 07h23 HE | Research and Markets
Dublin, April 28, 2022 (GLOBE NEWSWIRE) -- The "Allergy Immunotherapy Market, by Treatment Type, by Allergy Type, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity...
intrommune_icon_500x500.png
INT301 Continues to Meet Safety Goals in Phase 1 OMEGA Study in Adults with Peanut Allergy While Reaching Phase 2 Target Maintenance Dose
06 avr. 2022 08h30 HE | Intrommune Therapeutics
INT301 Met Safety Goals Across Eleven Dose Levels Patient Treatment Now Ongoing in Cohort 3 Intrommune Expands Study Scope to Explore MTD NEW YORK, April 06, 2022 (GLOBE NEWSWIRE) -- Intrommune...
intrommune_icon_500x500.png
Intrommune Reports Positive Update from Ongoing Phase 1 Study in Peanut Allergy
08 févr. 2022 08h30 HE | Intrommune Therapeutics
INT301 Met Safety Goals Across Four Dose Levels in Cohort 1 Patient Treatment Now Ongoing in Fully Enrolled Cohort 2 Intrommune Launches Series B Financing NEW YORK, Feb. 08, 2022 (GLOBE...